Momentum Biotechnologies ('Momentum'), a contract research organisation (CRO), announced on Wednesday that it has added Dr Kevin Bateman to its scientific advisory board.

Dr Bateman has more than 25 years of pharmaceutical industry experience and expertise concentrated on bringing new analytical, automation and data science capabilities to drug discovery and development programmes. He served as scientific associate vice president at Merck Research Laboratories prior to retiring earlier this year.

Dr Can Ozbal, CEO of Momentum, said, 'We are thrilled to have Kevin on our scientific advisory board. His long tenure as a drug hunter at Merck and thought leadership in the mass spec field will aid us as we further improve our high-throughput drug screening offerings and expand our lead identification services and solutions for our clients.'